The Pharma Solutions division of Piramal Pharma, Mumbai-based contract development and manufacturing company (CDMO), has announced the expansion of its antibody-drug conjugate (ADC) manufacturing capabilities at the Grangemouth facility in Scotland and investment in new Active Pharmaceutical Ingredients (API) infrastructure at the Morpeth facility in England. 

Taken together, these expansions and modernizations represent a total investment of approximately £55 million in the company's UK drug development and manufacturing operations and provide new employment opportunities for technical and operational staff.

The first phase of the expansion of the Grangemouth site will add two additional ADC production facilities to the existing three, which will be operational by the third quarter of 2023. 

This extension represents an investment of £45 million including a £2.4 million grant from Scottish Enterprise, Scotland's national business development agency.

The investment in API capacity at the Morpeth site, valued at approximately £10 million, includes new plant, infrastructure and utility systems. Piramal is investing £8 million directly while the UK Government is contributing £2 million to the project.